Register for our free email digests:
Welch Allyn Inc.
Division of Hill-Rom Holdings Inc.
Latest From Boryung Pharmaceuticals Co. Ltd.
AstraZeneca concludes week of four out-licensing transactions by selling US rights to Toprol XL to Aralez and ex-US rights to Rhinocort Aqua to J&J. Molecular Partners gets back rights to an IL-13/IL-17 inhibitor for pulmonary indications after a 2011 deal with Janssen unravels.
Amid limited resources and marketing capabilities, South Korean pharmas are increasingly opting for improved and orphan drugs as their ticket to major global markets. Several companies shared their varying strategies for international success during a recent symposium in Seoul.
Despite the South Korean pharma industry’s strong efforts to boost exports amid a challenging domestic environment, a domestic research report says the industry still lacks competitiveness in the global market and advises pharma firms to focus more on exports to emerging nations which have high growth potential.
The number of clinical trials conducted in South Korea has continued to climb on the back of domestic pharma firms’ efforts to transform themselves into R&D-focused companies and the government’s drive to nurture the biopharma industry.
- Diagnostic Equipment & Supplies
- Monitoring Equipment & Devices
- Therapeutic Areas
- Gynecological, Urological
- North America
- Parent & Subsidiaries
- Hill-Rom Holdings Inc.
- Senior Management
Stephen F Meyer, Pres. & CEO
Jon Soderberg, EVP & Chief Corp. Dev. Officer
Mike Ehrhart, EVP, Prod. Dev.
- Contact Info
Welch Allyn Inc.
Phone: (800) 535-6663
4341 State St. Rd.
P.O. Box 220 Skaneateles Falls, NY 13153
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.